Global Idiopathic Pulmonary Fibrosis
Global Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Comprehensive Study by Application (Hospital, Clinic, Others), Drugs (Systemic corticosteroids, Immunosuppressant drugs, Tyrosine kinase inhibitors, Antifibrotic agents), Diagnosis (Chest Imaging Studies, Lung Biopsy, Pulmonary Function Test, Oxygen Desaturation Study, Other Laboratory Tests) Players and Region - Global Market Outlook to 2026

Idiopathic Pulmonary Fibrosis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 200 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Idiopathic Pulmonary Fibrosis Market?

Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs over time results in reduced oxygen intake for an unknown reason. The symptoms of idiopathic pulmonary fibrosis are non-specific but most patients present with a gradual onset (often >6 mo) of exertional dyspnea and/or nonproductive cough. It is estimated that currently, more than 80,000 adults in the United States have IPF, and more than 30,000 new cases are diagnosed each year. Idiopathic pulmonary fibrosis affects each person differently and the disease progresses at varying rates.

The market study is being classified, by Application (Hospital, Clinic and Others) and major geographies with country level break-up.

MediciNova, Inc. (United States), C.H. Boehringer Sohn AG & Ko. KG (Germany), Roche Holding AG (Switzerland), Merck & Co., Inc. (United States), Baxter International (United States), Prometheus Laboratories Inc. (United States), Afferent Pharmaceuticals, Inc. (United States), Biogen Inc. (United States), Cipla Limited (India) and Bristol-Myers Squibb (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Amgen Inc. (United States) and FibroGen (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Idiopathic Pulmonary Fibrosis market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Idiopathic Pulmonary Fibrosis market by Type, Application and Region.

On the basis of geography, the market of Idiopathic Pulmonary Fibrosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Idiopathic Pulmonary Fibrosis in Adults
  • Rise in the Number of Diagnostic Centres in Developing Countries

Market Trend
  • Surge in the Cigarette-Smoking Population
  • Advancements in IPF Diagnostic and Treatment Methods

Restraints
  • Lack of Complete Cure Treatment for Idiopathic Pulmonary Fibrosis
  • Lack of Healthcare Infrastructure in Under Developed Countries

Opportunities
  • Increasing Geriatric Population Worldwide
  • Growth in the Healthcare Sector Around the Globe

Challenges
  • Stringent Government Rules and Regulations


In February 2019, Roche and Spark Therapeutics, Inc. has announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics.


Key Target Audience
Idiopathic Pulmonary Fibrosis Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospital
  • Clinic
  • Others
By Drugs
  • Systemic corticosteroids
  • Immunosuppressant drugs
  • Tyrosine kinase inhibitors
  • Antifibrotic agents

By Diagnosis
  • Chest Imaging Studies
  • Lung Biopsy
  • Pulmonary Function Test
  • Oxygen Desaturation Study
  • Other Laboratory Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Idiopathic Pulmonary Fibrosis in Adults
      • 3.2.2. Rise in the Number of Diagnostic Centres in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Surge in the Cigarette-Smoking Population
      • 3.4.2. Advancements in IPF Diagnostic and Treatment Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Idiopathic Pulmonary Fibrosis, by Application, Drugs, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Idiopathic Pulmonary Fibrosis (Value)
      • 5.2.1. Global Idiopathic Pulmonary Fibrosis by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Others
      • 5.2.2. Global Idiopathic Pulmonary Fibrosis by: Drugs (Value)
        • 5.2.2.1. Systemic corticosteroids
        • 5.2.2.2. Immunosuppressant drugs
        • 5.2.2.3. Tyrosine kinase inhibitors
        • 5.2.2.4. Antifibrotic agents
      • 5.2.3. Global Idiopathic Pulmonary Fibrosis by: Diagnosis (Value)
        • 5.2.3.1. Chest Imaging Studies
        • 5.2.3.2. Lung Biopsy
        • 5.2.3.3. Pulmonary Function Test
        • 5.2.3.4. Oxygen Desaturation Study
        • 5.2.3.5. Other Laboratory Tests
      • 5.2.4. Global Idiopathic Pulmonary Fibrosis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Idiopathic Pulmonary Fibrosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MediciNova, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter International (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Prometheus Laboratories Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Afferent Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Idiopathic Pulmonary Fibrosis Sale, by Application, Drugs, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Idiopathic Pulmonary Fibrosis (Value)
      • 7.2.1. Global Idiopathic Pulmonary Fibrosis by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Others
      • 7.2.2. Global Idiopathic Pulmonary Fibrosis by: Drugs (Value)
        • 7.2.2.1. Systemic corticosteroids
        • 7.2.2.2. Immunosuppressant drugs
        • 7.2.2.3. Tyrosine kinase inhibitors
        • 7.2.2.4. Antifibrotic agents
      • 7.2.3. Global Idiopathic Pulmonary Fibrosis by: Diagnosis (Value)
        • 7.2.3.1. Chest Imaging Studies
        • 7.2.3.2. Lung Biopsy
        • 7.2.3.3. Pulmonary Function Test
        • 7.2.3.4. Oxygen Desaturation Study
        • 7.2.3.5. Other Laboratory Tests
      • 7.2.4. Global Idiopathic Pulmonary Fibrosis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Idiopathic Pulmonary Fibrosis: by Application(USD Million)
  • Table 2. Idiopathic Pulmonary Fibrosis Hospital , by Region USD Million (2015-2020)
  • Table 3. Idiopathic Pulmonary Fibrosis Clinic , by Region USD Million (2015-2020)
  • Table 4. Idiopathic Pulmonary Fibrosis Others , by Region USD Million (2015-2020)
  • Table 5. Idiopathic Pulmonary Fibrosis: by Drugs(USD Million)
  • Table 6. Idiopathic Pulmonary Fibrosis Systemic corticosteroids , by Region USD Million (2015-2020)
  • Table 7. Idiopathic Pulmonary Fibrosis Immunosuppressant drugs , by Region USD Million (2015-2020)
  • Table 8. Idiopathic Pulmonary Fibrosis Tyrosine kinase inhibitors , by Region USD Million (2015-2020)
  • Table 9. Idiopathic Pulmonary Fibrosis Antifibrotic agents , by Region USD Million (2015-2020)
  • Table 10. Idiopathic Pulmonary Fibrosis: by Diagnosis(USD Million)
  • Table 11. Idiopathic Pulmonary Fibrosis Chest Imaging Studies , by Region USD Million (2015-2020)
  • Table 12. Idiopathic Pulmonary Fibrosis Lung Biopsy , by Region USD Million (2015-2020)
  • Table 13. Idiopathic Pulmonary Fibrosis Pulmonary Function Test , by Region USD Million (2015-2020)
  • Table 14. Idiopathic Pulmonary Fibrosis Oxygen Desaturation Study , by Region USD Million (2015-2020)
  • Table 15. Idiopathic Pulmonary Fibrosis Other Laboratory Tests , by Region USD Million (2015-2020)
  • Table 16. South America Idiopathic Pulmonary Fibrosis, by Country USD Million (2015-2020)
  • Table 17. South America Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 18. South America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 19. South America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 20. Brazil Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 21. Brazil Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 22. Brazil Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 23. Argentina Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 24. Argentina Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 25. Argentina Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 26. Rest of South America Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 27. Rest of South America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 28. Rest of South America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 29. Asia Pacific Idiopathic Pulmonary Fibrosis, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 32. Asia Pacific Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 33. China Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 34. China Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 35. China Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 36. Japan Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 37. Japan Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 38. Japan Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 39. India Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 40. India Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 41. India Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 42. South Korea Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 43. South Korea Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 44. South Korea Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 45. Taiwan Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 46. Taiwan Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 47. Taiwan Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 48. Australia Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 49. Australia Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 50. Australia Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 54. Europe Idiopathic Pulmonary Fibrosis, by Country USD Million (2015-2020)
  • Table 55. Europe Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 56. Europe Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 57. Europe Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 58. Germany Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 59. Germany Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 60. Germany Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 61. France Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 62. France Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 63. France Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 64. Italy Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 65. Italy Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 66. Italy Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 67. United Kingdom Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 68. United Kingdom Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 69. United Kingdom Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 70. Netherlands Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 71. Netherlands Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 72. Netherlands Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 73. Rest of Europe Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 74. Rest of Europe Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 75. Rest of Europe Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 76. MEA Idiopathic Pulmonary Fibrosis, by Country USD Million (2015-2020)
  • Table 77. MEA Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 78. MEA Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 79. MEA Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 80. Middle East Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 81. Middle East Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 82. Middle East Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 83. Africa Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 84. Africa Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 85. Africa Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 86. North America Idiopathic Pulmonary Fibrosis, by Country USD Million (2015-2020)
  • Table 87. North America Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 88. North America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 89. North America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 90. United States Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 91. United States Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 92. United States Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 93. Canada Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 94. Canada Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 95. Canada Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 96. Mexico Idiopathic Pulmonary Fibrosis, by Application USD Million (2015-2020)
  • Table 97. Mexico Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2015-2020)
  • Table 98. Mexico Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Idiopathic Pulmonary Fibrosis: by Application(USD Million)
  • Table 110. Idiopathic Pulmonary Fibrosis Hospital , by Region USD Million (2021-2026)
  • Table 111. Idiopathic Pulmonary Fibrosis Clinic , by Region USD Million (2021-2026)
  • Table 112. Idiopathic Pulmonary Fibrosis Others , by Region USD Million (2021-2026)
  • Table 113. Idiopathic Pulmonary Fibrosis: by Drugs(USD Million)
  • Table 114. Idiopathic Pulmonary Fibrosis Systemic corticosteroids , by Region USD Million (2021-2026)
  • Table 115. Idiopathic Pulmonary Fibrosis Immunosuppressant drugs , by Region USD Million (2021-2026)
  • Table 116. Idiopathic Pulmonary Fibrosis Tyrosine kinase inhibitors , by Region USD Million (2021-2026)
  • Table 117. Idiopathic Pulmonary Fibrosis Antifibrotic agents , by Region USD Million (2021-2026)
  • Table 118. Idiopathic Pulmonary Fibrosis: by Diagnosis(USD Million)
  • Table 119. Idiopathic Pulmonary Fibrosis Chest Imaging Studies , by Region USD Million (2021-2026)
  • Table 120. Idiopathic Pulmonary Fibrosis Lung Biopsy , by Region USD Million (2021-2026)
  • Table 121. Idiopathic Pulmonary Fibrosis Pulmonary Function Test , by Region USD Million (2021-2026)
  • Table 122. Idiopathic Pulmonary Fibrosis Oxygen Desaturation Study , by Region USD Million (2021-2026)
  • Table 123. Idiopathic Pulmonary Fibrosis Other Laboratory Tests , by Region USD Million (2021-2026)
  • Table 124. South America Idiopathic Pulmonary Fibrosis, by Country USD Million (2021-2026)
  • Table 125. South America Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 126. South America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 127. South America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 128. Brazil Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 129. Brazil Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 130. Brazil Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 131. Argentina Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 132. Argentina Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 133. Argentina Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 134. Rest of South America Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 135. Rest of South America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 136. Rest of South America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 137. Asia Pacific Idiopathic Pulmonary Fibrosis, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 139. Asia Pacific Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 140. Asia Pacific Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 141. China Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 142. China Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 143. China Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 144. Japan Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 145. Japan Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 146. Japan Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 147. India Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 148. India Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 149. India Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 150. South Korea Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 151. South Korea Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 152. South Korea Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 153. Taiwan Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 154. Taiwan Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 155. Taiwan Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 156. Australia Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 157. Australia Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 158. Australia Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 162. Europe Idiopathic Pulmonary Fibrosis, by Country USD Million (2021-2026)
  • Table 163. Europe Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 164. Europe Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 165. Europe Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 166. Germany Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 167. Germany Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 168. Germany Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 169. France Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 170. France Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 171. France Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 172. Italy Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 173. Italy Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 174. Italy Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 175. United Kingdom Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 176. United Kingdom Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 177. United Kingdom Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 178. Netherlands Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 179. Netherlands Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 180. Netherlands Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 181. Rest of Europe Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 182. Rest of Europe Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 183. Rest of Europe Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 184. MEA Idiopathic Pulmonary Fibrosis, by Country USD Million (2021-2026)
  • Table 185. MEA Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 186. MEA Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 187. MEA Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 188. Middle East Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 189. Middle East Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 190. Middle East Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 191. Africa Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 192. Africa Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 193. Africa Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 194. North America Idiopathic Pulmonary Fibrosis, by Country USD Million (2021-2026)
  • Table 195. North America Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 196. North America Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 197. North America Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 198. United States Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 199. United States Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 200. United States Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 201. Canada Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 202. Canada Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 203. Canada Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 204. Mexico Idiopathic Pulmonary Fibrosis, by Application USD Million (2021-2026)
  • Table 205. Mexico Idiopathic Pulmonary Fibrosis, by Drugs USD Million (2021-2026)
  • Table 206. Mexico Idiopathic Pulmonary Fibrosis, by Diagnosis USD Million (2021-2026)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Idiopathic Pulmonary Fibrosis: by Application USD Million (2015-2020)
  • Figure 5. Global Idiopathic Pulmonary Fibrosis: by Drugs USD Million (2015-2020)
  • Figure 6. Global Idiopathic Pulmonary Fibrosis: by Diagnosis USD Million (2015-2020)
  • Figure 7. South America Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 8. Asia Pacific Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 9. Europe Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 10. MEA Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 11. North America Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 12. Global Idiopathic Pulmonary Fibrosis share by Players 2020 (%)
  • Figure 13. Global Idiopathic Pulmonary Fibrosis share by Players (Top 3) 2020(%)
  • Figure 14. Global Idiopathic Pulmonary Fibrosis share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. MediciNova, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. MediciNova, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2020
  • Figure 20. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 25. Baxter International (United States) Revenue: by Geography 2020
  • Figure 26. Prometheus Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Prometheus Laboratories Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Afferent Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Afferent Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Biogen Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 33. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 34. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 36. Global Idiopathic Pulmonary Fibrosis: by Application USD Million (2021-2026)
  • Figure 37. Global Idiopathic Pulmonary Fibrosis: by Drugs USD Million (2021-2026)
  • Figure 38. Global Idiopathic Pulmonary Fibrosis: by Diagnosis USD Million (2021-2026)
  • Figure 39. South America Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 40. Asia Pacific Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 41. Europe Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 42. MEA Idiopathic Pulmonary Fibrosis Share (%), by Country
  • Figure 43. North America Idiopathic Pulmonary Fibrosis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • MediciNova, Inc. (United States)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Roche Holding AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Baxter International (United States)
  • Prometheus Laboratories Inc. (United States)
  • Afferent Pharmaceuticals, Inc. (United States)
  • Biogen Inc. (United States)
  • Cipla Limited (India)
  • Bristol-Myers Squibb (United States)
Additional players considered in the study are as follows:
Amgen Inc. (United States) , FibroGen (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation